The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2016:
- 23 negotiations are currently underway with 5 files added since the last update on March 31, 2016:
- Arnuity Ellipta (fluticasone furoate): used for the treatment of asthma;
- Breo Ellipta (fluticasone furoate/vilanterol): used for treatment of asthma;
- Rosiver (ivermectin): used to treat rosacea;
- Technivie (ombitasvir/paritaprevir/ritonavir): used for the treatment of Hepatitis C; and
- Zepatier (elbasvir grazoprevir): used for the treatment of Hepatitis C.
- 105 joint negotiations have been completed with 5 files completed since the last update on March 31, 2016:
- Jardiance (empagliflozin): used to treat Type 2 diabetes mellitus;
- Tobi Podhaler (tobramycin): used for the management of cystic fibrosis;
- Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin): used to treat Type 2 diabetes mellitus;
- Xeljanz (tofacitinib): used to treat rheumatoid arthritis; and
- Simponi (golimumab) IV: used to treat rheumatoid arthritis.
Please note: Negotiations involving Simponi were closed as an agreement was not reached.
- 37 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update on March 31, 2016.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with 1 new file added since the last update on March 31, 2016:
- Humalog 200 units/ml (insulin lispro): used to treat Type 1 and 2 diabetes
For more information, please consult the pCPA’s website.